Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 13 February, 2020

BkofA Merrill Lynch

Form 38.5 (a) - Allergan

RNS Number : 9331C
Bank of America Merrill Lynch
13 February 2020
 

FORM 38.5(a)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED
INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 

1.

KEY INFORMATION

Name of exempt principal trader:

Merrill Lynch International

Company dealt in

Allergan PLC

Class of relevant security to which the
dealings being disclosed relate(Note 1)

Common - IE00BY9D5467

Date of dealing

12/02/2020

 

2.

DEALINGS (Note 2)

(a)

Purchases and sales

Total number of relevant securities acquired

Highest price paid (Note 3)

Lowest price paid (Note 3)

1,339

202.15 USD

202.03 USD

 

Total number of securities disposed

Highest price received (Note 3)

Lowest price received (Note 3)

N/A

N/A

N/A

 

(b)

Derivatives transactions (other than options transactions)

Product name,
e.g. CFD

Nature of transaction
(Note 4)

Number of relevant securities
(Note 5)

Price per unit
(Note 3)

N/A

N/A

N/A

N/A

 

(c)

Options transactions in respect of existing relevant securities

(i)

Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc

Expiry date

Option money paid/ received per unit (Note 3)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit
(Note 3)

N/A

N/A

N/A

 

3.

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

Borrow of 240 shares


 

Date of disclosure

13/02/2020

Contact name

Tolu Tade

Telephone number

+44207 996 3410

Name of offeree/offerer with
which connected

AbbVie Inc

Nature of connection(Note 6)

Advisor to - AbbVie Inc

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISESFIFFDESSEEE

a d v e r t i s e m e n t